First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Aptevo Therapeutics Inc.

    APVO · 3 developments mapped · last assessed 2026-09-03

    Market Ontology has mapped 3 macro, policy, and market developments to Aptevo Therapeutics Inc. since 2026-08-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for APVO yet, so no modelled value is shown. The APVO valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run APVO on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for APVO. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Aptevo Therapeutics Reports 93% Clinical Benefit Rate with Mipletamig Triplet in AML

      Direct positive clinical trial results for lead candidate, increasing probability of regulatory approval and future commercialization.

      · Moves probability of success (pos) for mipletamig, peak sales estimates for mipletamig, discount rate (reflecting reduced risk)

    • Open question

      Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.

      Dilution from equity issuance; long-term success of collaboration is uncertain.

      · Moves future share count, long term success rate of new drug development

    What changed, by assumption

    Probability of success (pos) for mipletamig
    • 2026-09-03Aptevo Therapeutics Reports 93% Clinical Benefit Rate with Mipletamig Triplet in AML
    Probability of success for pipeline assets
    • 2026-08-14Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.
    Future share count
    • 2026-08-14Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-14Valuation multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.0.70
    2026-08-14Share countBullishPrimary equity issuance increases diluted share count.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-03Aptevo Therapeutics Reports 93% Clinical Benefit Rate with Mipletamig Triplet in AMLBullish1-3m0.90
    2026-08-14Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.Bullish1-3m0.70
    2026-08-14Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.mixed1-5y0.40